Stroke patients develop antibodies that react with components of n-methyl-d-aspartate receptor subunit 1 in proportion to lesion size

Stroke

Volumn 44, Issue 8, 2013, Pages 2212-2219

  Kalev Zylinska, Maggie L ^a,b   Symes, Wymond ^a   Little, Kevin C E ^a   Sun, Peng ^a   Wen, Daying ^a   Qiao, Linzi ^a   Young, Deborah ^a   During, Matthew J ^a,d   Barber, P Alan ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

antibody; GluN1; imaging; ischemic; NMDAR; NR1

Indexed keywords

IMMUNOGLOBULIN G; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1 ANTIBODY; RECEPTOR ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SEX DIFFERENCE; STROKE PATIENT; WESTERN BLOTTING;

ANTIBODY; GLUN1; IMAGING; ISCHEMIC; NMDAR; NR1;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; STROKE;

EID: 84880825962     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001235     Document Type: Article

References (37)

1. Becker KJ. Sensitization and tolerization to brain antigens in stroke. Neuroscience. 2009;158:1090-1097.
2. Bornstein NM, Aronovich B, Korczyn AD, Shavit S, Michaelson DM, Chapman J. Antibodies to brain antigens following stroke. Neurology. 2001;56:529-530. (Pubitemid 32172881)
3. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.
4. Dambinova SA, Khounteev GA, Skoromets AA. Multiple panel of bio-markers for TIA/stroke evaluation. Stroke. 2002;33:1181-1182. (Pubitemid 34517030)
5. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient isch-emic attack and stroke. Clin Chem. 2003;49:1752-1762. (Pubitemid 37194244)
6. Weissman JD, Khunteev GA, Heath R, Dambinova SA. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011;300:97-102.
7. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurode-generation. Pfugers Arch. 2010;460:525-542.
8. Arundine M, Tymianski M. Molecular mechanisms of glutamate-depen-dent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci. 2004;61:657-668. (Pubitemid 38446410)
9. Taghibiglou C, Martin HG, Lai TW, Cho T, Prasad S, Kojic L, et al. Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat Med. 2009;15:1399-1406.
10. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62:405-496.
11. Gingrich MB, Junge CE, Lyuboslavsky P, Traynelis SF. Potentiation of NMDA receptor function by the serine protease thrombin. J Neurosci. 2000;20:4582-4595. (Pubitemid 30396624)
12. Fernández-Monreal M, López-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, et al. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J Biol Chem. 2004;279:50850-50856. (Pubitemid 40017823)
13. Samson AL, Nevin ST, Croucher D, Niego B, Daniel PB, Weiss TW, et al. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem. 2008;107:1091-1101.
14. Pauly T, Ratliff M, Pietrowski E, Neugebauer R, Schlicksupp A, Kirsch J, et al. Activity-dependent shedding of the NMDA receptor glycine binding site by matrix metalloproteinase 3: a PUTATIVE mechanism of postsynaptic plasticity. PLoS One. 2008;3:e2681.
15. Yuan H, Vance KM, Junge CE, Geballe MT, Snyder JP, Hepler JR, et al. The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem. 2009;284:12862-12873.
16. Gascón S, Sobrado M, Roda JM, Rodríguez-Peña A, Díaz-Guerra M. Excitotoxicity and focal cerebral ischemia induce truncation of the NR2A and NR2B subunits of the NMDA receptor and cleavage of the scaffolding protein PSD-95. Mol Psychiatry. 2008;13:99-114. (Pubitemid 350275182)
17. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7:59-64.
18. Dambinova SA, Bettermann K, Glynn T, Tews M, Olson D, Weissman JD, et al. Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One. 2012;7:e42362.
19. Planas AM, Gómez-Choco M, Urra X, Gorina R, Caballero M, Chamorro Á. Brain-derived antigens in lymphoid tissue of patients with acute stroke. J Immunol. 2012;188:2156-2163.
20. Bokesch PM, Izykenova GA, Justice JB, Easley KA, Dambinova SA. NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke. 2006;37:1432-1436. (Pubitemid 44305722)
21. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, et al. Glycine binding primes NMDA receptor internalization. Nature. 2003;422:302-307. (Pubitemid 36378356)
22. Standley S, Roche KW, McCallum J, Sans N, Wenthold RJ. PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants. Neuron. 2000;28:887-898. (Pubitemid 32038079)
23. Talukder I, Wollmuth LP. Local constraints in either the GluN1 or GluN2 subunit equally impair NMDA receptor pore opening. J Gen Physiol. 2011;138:179-194.
24. Bradley J, Carter SR, Rao VR, Wang J, Finkbeiner S. Splice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression. J Neurosci. 2006;26:1065-1076. (Pubitemid 43237038)
25. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355:1670-1674. (Pubitemid 30248478)
26. Husebye ES, Sthoeger ZM, Dayan M, Zinger H, Elbirt D, Levite M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1210-1213. (Pubitemid 41113359)
27. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001;7:1189-1193. (Pubitemid 33063773)
28. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, et al. An oral vaccine against NMDAR1 with effcacy in experimental stroke and epilepsy. Science. 2000;287:1453-1460. (Pubitemid 30127132)
29. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol. 2006;33:1553-1558. (Pubitemid 44168826)
30. Kalev-Zylinska ML, Symes W, Young D, During MJ. Knockdown and overexpression of NR1 modulates NMDA receptor function. Mol Cell Neurosci. 2009;41:383-396.
31. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol. 2007;28:12-18. (Pubitemid 44960159)
32. Zierath D, Thullbery M, Hadwin J, Gee JM, Savos A, Kalil A, et al. CNS immune responses following experimental stroke. Neurocrit Care. 2010;12:274-284.
33. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25-36. (Pubitemid 46214241)
34. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58:594-604. (Pubitemid 41377223)
35. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74.
36. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-1098.
37. Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci. 2012;32:11082-11094.